Ecovyst Q2 Sales Surge 42%, Raises Full-Year Outlook on Strong Demand and Calabrian Acquisition
ECVT sits 75% above its 52-week low of $7.41.
Summary
Ecovyst reported Q2 2026 sales of $250 million, up 42% year-over-year, and raised full-year Adjusted EBITDA guidance to $195-$207 million, driven by strong demand and the Calabrian acquisition.
Updates
· Reuters — Q2 sales of $250 million beat the $237.48 million consensus; adjusted EPS of $0.21 topped estimates. Full-year 2026 sales guidance raised to $1.02 billion-$1.06 billion from $890 million-$970 million.
Key Events · Earnings and Guidance · ECVT
-
Q2 Sales Surge 42%
Sales reached $250.0 million, up $73.9 million from $176.1 million in Q2 2025, driven by higher volumes and pricing in both regenerated and virgin sulfuric acid.
-
Adjusted EBITDA Up 27%
Adjusted EBITDA rose to $53.1 million from $41.9 million, with margin of 21.2%, reflecting strong operating leverage and favorable net pricing.
-
Full-Year Guidance Raised
2026 Adjusted EBITDA guidance increased to $195-$207 million (from $180-$195 million), including $10-$12 million from Calabrian in H2; Adjusted Diluted EPS now seen at $0.58-$0.72.
-
Calabrian Acquisition Completed
The $190 million Calabrian deal closed June 30, 2026, expanding Ecovyst's sulfur dioxide platform into mining, water treatment, and pharma; integration synergies expected.
Analysis · ECVT · Industrial Applications And Services
A standout quarter saw sales jump 42% to $250 million, beating consensus, while full-year Adjusted EBITDA guidance was raised by $15 million at the midpoint. The performance reflects robust demand for regenerated and virgin sulfuric acid, plus the first contribution from the newly acquired Calabrian business. With $176 million in liquidity and no share repurchases during the quarter, the company is preserving cash for integration and growth. This is a clear positive signal that the core business is accelerating and the Calabrian deal is already adding value.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ECVT was trading at $13.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $7.41 to $15.09. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.